Cite
Cell-Free Plasma DNA-Guided Treatment With Osimertinib in Patients With Advanced EGFR-Mutated NSCLC.
MLA
Buder, Anna, et al. “Cell-Free Plasma DNA-Guided Treatment With Osimertinib in Patients With Advanced EGFR-Mutated NSCLC.” Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer, vol. 13, no. 6, June 2018, pp. 821–30. EBSCOhost, https://doi.org/10.1016/j.jtho.2018.02.014.
APA
Buder, A., Hochmair, M. J., Schwab, S., Bundalo, T., Schenk, P., Errhalt, P., Mikes, R. E., Absenger, G., Patocka, K., Baumgartner, B., Setinek, U., Burghuber, O. C., Prosch, H., Pirker, R., & Filipits, M. (2018). Cell-Free Plasma DNA-Guided Treatment With Osimertinib in Patients With Advanced EGFR-Mutated NSCLC. Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer, 13(6), 821–830. https://doi.org/10.1016/j.jtho.2018.02.014
Chicago
Buder, Anna, Maximilian J Hochmair, Sophia Schwab, Tatjana Bundalo, Peter Schenk, Peter Errhalt, Romana E Mikes, et al. 2018. “Cell-Free Plasma DNA-Guided Treatment With Osimertinib in Patients With Advanced EGFR-Mutated NSCLC.” Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer 13 (6): 821–30. doi:10.1016/j.jtho.2018.02.014.